Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Aug 1:177:249-257.
doi: 10.1016/j.drugalcdep.2017.04.020. Epub 2017 Jun 10.

A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults

Kevin M Gray  1 , Susan C Sonne  2 , Erin A McClure  3 , Udi E Ghitza  4 , Abigail G Matthews  5 , Aimee L McRae-Clark  6 , Kathleen M Carroll  7 , Jennifer S Potter  8 , Katharina Wiest  9 , Larissa J Mooney  10 , Albert Hasson  11 , Sharon L Walsh  12 , Michelle R Lofwall  13 , Shanna Babalonis  14 , Robert W Lindblad  15 , Steven Sparenborg  16 , Aimee Wahle  17 , Jacqueline S King  18 , Nathaniel L Baker  19 , Rachel L Tomko  20 , Louise F Haynes  21 , Ryan G Vandrey  22 , Frances R Levin  23
Affiliations
Randomized Controlled Trial

A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults

Kevin M Gray et al. Drug Alcohol Depend. .

Abstract

Background: Cannabis use disorder (CUD) is a prevalent and impairing condition, and established psychosocial treatments convey limited efficacy. In light of recent findings supporting the efficacy of N-acetylcysteine (NAC) for CUD in adolescents, the objective of this trial was to evaluate its efficacy in adults.

Methods: In a 12-week double-blind randomized placebo-controlled trial, treatment-seeking adults ages 18-50 with CUD (N=302), enrolled across six National Drug Abuse Treatment Clinical Trials Network-affiliated clinical sites, were randomized in a 1:1 ratio to a 12-week course of NAC 1200mg (n=153) or placebo (n=149) twice daily. All participants received contingency management (CM) and medical management. The primary efficacy measure was the odds of negative urine cannabinoid tests during treatment, compared between NAC and placebo participants.

Results: There was not statistically significant evidence that the NAC and placebo groups differed in cannabis abstinence (odds ratio=1.00, 95% confidence interval 0.63-1.59, p=0.984). Overall, 22.3% of urine cannabinoid tests in the NAC group were negative, compared with 22.4% in the placebo group. Many participants were medication non-adherent; exploratory analysis within medication-adherent subgroups revealed no significant differential abstinence outcomes by treatment group.

Conclusions: In contrast with prior findings in adolescents, there is no evidence that NAC 1200mg twice daily plus CM is differentially efficacious for CUD in adults when compared to placebo plus CM. This discrepant finding between adolescents and adults with CUD may have been influenced by differences in development, cannabis use profiles, responses to embedded behavioral treatment, medication adherence, and other factors.

Trial registration: ClinicalTrials.gov NCT01675661.

Keywords: Addiction; Cannabis; Cessation; Marijuana; N-acetylcysteine; Pharmacotherapy; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Gray has received research support (medication only) from Pfizer. McRae-Clark has served as a consultant for Insys Pharmaceuticals and has received research support (medication only) from Pfizer. Walsh has received research support from Cerecor, Inc., and Braeburn Pharmaceuticals; has served as a consultant for AstraZeneca, Braeburn Pharmaceuticals, Camurus, Daiichi Sankyo, DURECT, Eli Lilly & Co., INSYS, Lightlake Therapeutics, KemPharm, Neurocrine, Novartis, Pfizer, Sun Pharma, and US WorldMeds; and has received speaker’s honoraria from PCM Scientific through unrestricted grants from Gilead, Indivior, and Merck. Lofwall has served as a consultant for Braeburn Pharmaceuticals, CVS Caremark, and PCM Scientific, and has received research support from Braeburn Pharmaceuticals. Vandrey has served as a consultant for Zynerba Pharmaceuticals, Battelle Memorial Institute, and CW Botanicals, and has served on an advisory panel for Insys Therapeutics. Levin has served as a consultant for GW Pharmaceuticals and Major League Baseball, and has received research support (medication only) from US WorldMeds. Sonne, McClure, Ghitza, Matthews, Carroll, Potter, Wiest, Mooney, Hasson, Babalonis, Lindblad, Sparenborg, Wahle, King, Tomko and Haynes report no competing interests.

Figures

Figure 1
Figure 1
CONSORT Diagram
Figure 2
Figure 2
Intent-to-treat urine cannabinoid test results BL=Baseline; NAC=N-acetylcysteine
Figure 3
Figure 3
Baseline tobacco use status and intent-to-treat urine cannabinoid test results BL=Baseline; NAC=N-acetylcysteine
Figure 4
Figure 4
Race and intent-to-treat urine cannabinoid test results BL=Baseline; NAC=N-acetylcysteine
See this image and copyright information in PMC

References

    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. fourth. Author; Washington, DC: 2000. text rev.
    1. Avants SK, Margolin A, Holford TR, Kosten TR. A randomized controlled trial of auricular acupuncture for cocaine dependence. Arc Intern Med. 2000;160:2305–2312. - PubMed
    1. Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, Kalivas PW. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci. 2003;6:743–749. - PubMed
    1. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988;43:72–78. - PubMed
    1. Budney AJ, Moore BA. Development and consequences of cannabis dependence. J Clin Pharmacol. 2002;42(Suppl 11):28–33. - PubMed

Publication types

Associated data